This is a repository copy of Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/103435/

Version: Supplemental Material

Article:
Ghislain, I, Zikos, E, Coens, C et al. (11 more authors) (2016) Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. The Lancet Oncology, 17 (7). e294-e304. ISSN 1470-2045
https://doi.org/10.1016/s1470-2045(16)30099-7

© 2016, Elsevier. This is an author produced version of a paper published in The Lancet Oncology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Figures

Figure 1: Selection Strategy – Flowchart of the inclusion and exclusion of studies

Exclusion criteria: 182 studies

- No ABC specific/other sites 59
- No medical treatment 54
- Duplicates 10
- Survivorship studies 9
- Bone related complications due to ABC 7
- Cost effectiveness studies 6
- Lymphatic nodes population 5
- Patient interviews 4
- Adverse event reporting instead of QoL 4
- N < 50 3
- No HRQOL endpoint 3
- Prognostic studies 3
- Protocol summaries 3
- Brain metastasis 2
- Included in our previous review 2
- Other 8

Eligibility criteria: 49 Randomized Clinical Trials (64 articles)

Diagnosed ABC with N ≥ 50, age > 18, regular oncology treatment*, including HRQOL data, with patient-reported outcomes (PRO) assessment.

*Chemotherapy, radiation therapy, targeted therapy, endocrine or hormonal treatment (psychological or supplementary interventions were excluded).

Figure 2: Comparison between the 2 spans of reviews